ACADACADIA Pharmaceuticals Inc.

$4B

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$224M+79.2% YoY

Gross Profit

$205M91.8% margin

Operating Income

-$247M-110.6% margin

Net Income

-$245M-109.6% margin

EPS (Diluted)

$-1.94

Cash Flow

Operating Cash Flow

-$167M

Free Cash Flow

-$170M

Stock-Based Comp.

$82M

Balance Sheet

Total Assets

$540M

Total Liabilities

$61M

Stockholders' Equity

$479M

Cash & Equivalents

$135M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$224M	$125M	+79.2%
Gross Profit	$205M	$112M	+83.7%
Operating Income	-$247M	-$292M	+15.4%
Net Income	-$245M	-$289M	+15.3%

ACAD FY 2018 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena